Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Net Cash Flow (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Net Cash Flow for 4 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 24.69% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $808516.0, a 21.16% decrease, with the full-year FY2024 number at -$483631.0, down 126.64% from a year prior.
  • Net Cash Flow was $2.1 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$1.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $2.2 million in Q3 2023 to a low of -$1.6 million in Q4 2024.
  • A 4-year average of $252392.5 and a median of -$130230.0 in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 816.57% in 2023, then plummeted 12409.58% in 2024.
  • 60 Degrees Pharmaceuticals' Net Cash Flow stood at -$193251.0 in 2022, then surged by 32.61% to -$130230.0 in 2023, then plummeted by 1158.81% to -$1.6 million in 2024, then skyrocketed by 231.0% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Net Cash Flow are $2.1 million (Q3 2025), -$1.5 million (Q2 2025), and $1.8 million (Q1 2025).